GlassScriptPhysician profile
Angela Tan
NPI 1750065603
$1,396.43
in general payments reported to CMS, 2019-2025
12 companies · $919 in 2025
The $919 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56.44 · 2024: $421 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $374.88 | 2024-2025 | Yescarta |
| Abbvie INC. | $365.20 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $224.12 | 2024-2025 | Sylvant |
| Astrazeneca Pharmaceuticals LP | $147.20 | 2024-2025 | Calquence |
| Lilly USA, LLC | $75.00 | 2025 | Jaypirca |
| Genmab U.S., INC. | $48.24 | 2024 | Epkinly |
| Novartis Pharmaceuticals Corporation | $47.16 | 2024 | |
| Daiichi Sankyo INC. | $29.19 | 2023 | |
| Emd Serono, INC. | $27.25 | 2023 | Bavencio |
| Tersera Therapeutics LLC | $25.86 | 2025 | Xermelo |
| Merck Sharp & Dohme LLC | $16.42 | 2024 | Keytruda |
| Pfizer INC. | $15.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.